NASDAQ:ACET Adicet Bio (ACET) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free ACET Stock Alerts $2.35 +0.02 (+0.86%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.31▼$2.4050-Day Range$1.95▼$3.3852-Week Range$1.10▼$7.50Volume529,955 shsAverage Volume1.81 million shsMarket Capitalization$193.05 millionP/E RatioN/ADividend YieldN/APrice Target$12.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Adicet Bio alerts: Email Address Adicet Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside446.1% Upside$12.83 Price TargetShort InterestBearish7.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 14 Articles This WeekInsider TradingAcquiring Shares$7.50 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.72) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 starsMedical Sector409th out of 938 stocksPharmaceutical Preparations Industry185th out of 417 stocks 3.3 Analyst's Opinion Consensus RatingAdicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.83, Adicet Bio has a forecasted upside of 446.1% from its current price of $2.35.Amount of Analyst CoverageAdicet Bio has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.07% of the outstanding shares of Adicet Bio have been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adicet Bio has recently increased by 2.65%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACET. Previous Next 2.5 News and Social Media Coverage News SentimentAdicet Bio has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Adicet Bio this week, compared to 2 articles on an average week.Search InterestOnly 17 people have searched for ACET on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat Follows11 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 10% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,500,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders29.50% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adicet Bio are expected to decrease in the coming year, from ($1.72) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Adicet Bio Stock (NASDAQ:ACET)Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical trial for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-270 that is in preclinical stage for the treatment of renal cell carcinoma and potential solid tumor; and ADI-002, which is undergoing preclinical studies for the treatment of hepatocellular carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.Read More ACET Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACET Stock News HeadlinesMarch 28, 2024 | businesswire.comAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | investorplace.comThe Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 28, 2024 | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarch 23, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Adicet Bio, Inc. (NASDAQ:ACET) Lifted by AnalystMarch 23, 2024 | americanbankingnews.comEquities Analysts Issue Forecasts for Adicet Bio, Inc.'s Q1 2024 Earnings (NASDAQ:ACET)March 22, 2024 | americanbankingnews.comAdicet Bio (NASDAQ:ACET) Stock Rating Upgraded by StockNews.comMarch 21, 2024 | finance.yahoo.comAdicet Bio Inc (ACET) Reports Q4 and Full Year 2023 Financial ResultsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 21, 2024 | finance.yahoo.comAre Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?March 21, 2024 | markets.businessinsider.comAdicet Bio’s Promising Drug Pipeline and Buy Rating JustificationMarch 21, 2024 | americanbankingnews.comAdicet Bio's (ACET) "Buy" Rating Reaffirmed at HC WainwrightMarch 21, 2024 | americanbankingnews.comAdicet Bio (NASDAQ:ACET) Earns Outperform Rating from WedbushMarch 21, 2024 | americanbankingnews.comAdicet Bio (NASDAQ:ACET) Stock Rating Reaffirmed by Canaccord Genuity GroupMarch 20, 2024 | markets.businessinsider.comBuy Recommendation for Adicet Bio Amid Promising Autoimmune and Cancer Therapy DevelopmentsMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial FootingMarch 20, 2024 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on Adicet Bio (ACET)March 19, 2024 | investorplace.comACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023March 19, 2024 | benzinga.comAdicet Bio: Q4 Earnings InsightsMarch 19, 2024 | markets.businessinsider.comAdicet Bio, Inc Q4 loss drops in line with estimatesMarch 19, 2024 | businesswire.comAdicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressMarch 11, 2024 | businesswire.comAdicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 5, 2024 | investorplace.com3 High-Risk Stocks That Could Pay Off in the MillionsFebruary 29, 2024 | businesswire.comAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)February 27, 2024 | investorplace.com7 Top-Tier Penny Stocks for a Smart BetFebruary 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 19, 2024 | finance.yahoo.comACET Apr 2024 7.500 callSee More Headlines Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:ACET CUSIP00444610 CIK2034 Webwww.aceto.com Phone(650) 503-9095FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Target$12.83 High Stock Price Target$27.00 Low Stock Price Target$5.00 Potential Upside/Downside+446.1%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.63% Return on Assets-48.16% Debt Debt-to-Equity RatioN/A Current Ratio8.41 Quick Ratio8.41 Sales & Book Value Annual Sales$24.99 million Price / Sales7.73 Cash FlowN/A Price / Cash FlowN/A Book Value$2.43 per share Price / Book0.97Miscellaneous Outstanding Shares82,150,000Free Float57,919,000Market Cap$193.05 million OptionableOptionable Beta1.87 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Chen Schor BA (Age 52)CPA, M.B.A., CEO, President & Director Comp: $899.58kDr. Aya Jakobovits Ph.D. (Age 68)Founder & Independent Director Comp: $40kDr. Blake Aftab Ph.D. (Age 43)Senior VP & Chief Scientific Officer Comp: $675.04kDr. Francesco Galimi M.D. (Age 56)Ph.D., Chief Medical Officer & Senior VP Comp: $680.37kMr. Brian Nicholas Harvey (Age 63)Chief Financial Officer Comp: $596.79kDr. Donald Healey Ph.D. (Age 62)Chief Technology Officer Ms. Amy LockeChief Human Resource OfficerDr. Nancy L. Boman M.D.Ph.D., Senior VP & Chief Regulatory OfficerMore ExecutivesKey CompetitorsAmylyx PharmaceuticalsNASDAQ:AMLXscPharmaceuticalsNASDAQ:SCPHRepare TherapeuticsNASDAQ:RPTXProQR TherapeuticsNASDAQ:PRQRRenovaroNASDAQ:RENBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 12,689 shares on 3/11/2024Ownership: 2.402%Goldman Sachs Group Inc.Sold 30,898 shares on 3/1/2024Ownership: 0.041%GSA Capital Partners LLPSold 121,494 shares on 2/16/2024Ownership: 0.029%Occudo Quantitative Strategies LPSold 4,851 shares on 2/15/2024Ownership: 0.109%Citadel Advisors LLCSold 3,300 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ACET Stock Analysis - Frequently Asked Questions Should I buy or sell Adicet Bio stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACET shares. View ACET analyst ratings or view top-rated stocks. What is Adicet Bio's stock price target for 2024? 8 brokers have issued 12-month price targets for Adicet Bio's shares. Their ACET share price targets range from $5.00 to $27.00. On average, they predict the company's stock price to reach $12.83 in the next year. This suggests a possible upside of 446.1% from the stock's current price. View analysts price targets for ACET or view top-rated stocks among Wall Street analysts. How have ACET shares performed in 2024? Adicet Bio's stock was trading at $1.89 on January 1st, 2024. Since then, ACET shares have increased by 24.3% and is now trading at $2.35. View the best growth stocks for 2024 here. When is Adicet Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ACET earnings forecast. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) issued its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.03. What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE). Who are Adicet Bio's major shareholders? Adicet Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RTW Investments LP (5.89%), Vanguard Group Inc. (2.40%), Vanguard Group Inc. (2.40%), Norges Bank (0.61%), Nuveen Asset Management LLC (0.28%) and Dimensional Fund Advisors LP (0.22%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Jay P Elliott, Orbimed Advisors Llc and Steve Dubin. View institutional ownership trends. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACET) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.